首页NBY • NYSEAMERICAN
add
NovaBay Pharmaceuticals Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 244.10万 | -1.61% |
经营支出 | 265.40万 | 12.46% |
净收入 | -121.20万 | 31.02% |
净利润率 | -49.65 | 29.89% |
每股收益 | -0.59 | 95.41% |
息税折旧摊销前利润 | -105.20万 | -53.58% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 77.60万 | -77.65% |
总资产 | 387.70万 | -69.83% |
负债总额 | 280.50万 | -51.76% |
权益总额 | 107.20万 | — |
发行在外的股份 | 488.57万 | — |
市净率 | 3.26 | — |
资产回报率 | -68.00% | — |
资本回报率 | -142.34% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -121.20万 | 31.02% |
来自运营的现金 | -206.10万 | -466.21% |
投资现金 | -2000.00 | -100.00% |
融资现金 | 208.90万 | 462.05% |
现金净变动 | 2.60万 | 102.13% |
自由现金流 | -147.94万 | -433.66% |
简介
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.
and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
成立时间
2000
员工数量
25
